Đang chuẩn bị liên kết để tải về tài liệu:
Ebook BNF 74 september 2017 – march 2018: Part 2

(BQ) Part 2 book “BNF 74 september 2017 – march 2018” has contents: Genito-urinary system, immune system and malignant disease, musculoskeletal system, emergency treatment of poisoning, blood and nutrition, ear, nose and oropharynx, and other contents. | Urinary frequency, enuresis, and incontinence 731 BNF 74 Chapter 7 Genito-urinary system 7 1 Bladder and urinary disorders 1.1 Urinary frequency, enuresis, and incontinence 1.2 Urinary retention 1.3 Urological pain page 731 731 736 742 2 Bladder instillations and urological surgery 3 Contraception Contraception, combined Contraception, devices Contraception, emergency Contraception, oral progestogen-only Contraception, parenteral progestogen-only Contraception, spermicidal 4 Erectile and ejaculatory conditions 4.1 Erectile dysfunction 3.1 3.2 3.3 3.4 3.5 3.6 743 745 749 756 757 758 762 764 765 765 1 Bladder and urinary disorders 1.1 Urinary frequency, enuresis, and incontinence Urinary frequency, enuresis and incontinence Urinary frequency and incontinence Incontinence in adults which arises from detrusor instability is managed by combining drug therapy with conservative methods for managing urge incontinence such as pelvic floor exercises and bladder training; stress incontinence is generally managed by non-drug methods. Duloxetine p. 350 can be added and is licensed for the treatment of moderate to severe stress incontinence in women; it may be more effective when used as an adjunct to pelvic floor exercises. Antimuscarinic drugs reduce symptoms of urgency and urge incontinence and increase bladder capacity. Oxybutynin hydrochloride p. 733 also has a direct relaxant effect on urinary smooth muscle. Side-effects limit the use of oxybutynin hydrochloride, but they may be reduced by starting at a lower dose. A modified-release preparation of oxybutynin hydrochloride is effective and has fewer sideeffects; a transdermal patch is also available. The efficacy and side-effects of tolterodine tartrate p. 735 are comparable to those of modified-release oxybutynin hydrochloride. Flavoxate hydrochloride p. 733 has less marked side-effects but it is also less effective. Darifenacin p. 732, fesoterodine fumarate p. 732, propiverine hydrochloride p. 735, solifenacin .